Fulcrum Therapeutics (FULC) Assets (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Assets data on file, last reported at $346.8 million in Q1 2026.

• On a quarterly basis, Assets rose 42.91% year-over-year to $346.8 million in Q1 2026; TTM through Mar 2026 was $346.8 million, a 42.91% increase from a year earlier, with the FY2025 full-year figure at $366.3 million, up 40.49% from the prior year.
• Assets for Q1 2026 stood at $346.8 million, down from $366.3 million in the prior quarter.
• Over the last five years, Assets for FULC reached as high as $366.3 million in Q4 2025 and fell as low as $195.2 million in Q2 2022.
• Historically, Assets has averaged $265.5 million across 5 years, with a median of $257.7 million in 2023.
• Across the five-year window, Assets jumped 53.83% in 2023 and dropped 27.57% in 2024, its largest moves.
• Year by year, Assets stood at $226.7 million in 2022, then rose by 13.68% to $257.7 million in 2023, then grew by 1.17% to $260.7 million in 2024, then soared by 40.49% to $366.3 million in 2025, then dropped by 5.33% to $346.8 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $346.8 million in Q1 2026, $366.3 million in Q4 2025, and $214.9 million in Q3 2025.